Innovating
Brain Resilience.
Caelium is a biopharmaceutical research and development company on a mission to make the brain stronger against degeneration caused by disease and injury. We develop therapeutic approaches designed to apply broadly across neurodegenerative conditions, including Alzheimer’s, Parkinson’s, Traumatic Brain Injury (TBI), and beyond.
"We focus on the structural integrity of the mind to prevent decline before it begins."
What Is Caelium
Caelium is a biopharmaceutical research and development company founded by internationally recognized leaders in brain imaging, radiology, and neurodegenerative disease research. The company was built on decades of work studying how brain degeneration unfolds across conditions such as Alzheimer’s and Traumatic Brain Injury.
Rather than approaching each disease in isolation, Caelium focuses on developing breakthrough therapies that address the shared degenerative processes underlying many neurological disorders. This research-driven foundation enables a more unified approach to fighting brain degeneration—transforming longstanding scientific insight into therapeutic treatments with the potential to impact a wide range of diseases and injuries.
The Team
Caelium is led by a distinguished collective of founders and researchers with deep expertise in neuroscience, advanced brain imaging, and translational medicine. Our team brings decades of experience from world-class clinical environments, dedicated to converting complex scientific discoveries into effective real-world therapies.
This commitment to clinical excellence and research integrity ensures that every breakthrough at Caelium is grounded in rigorous science and driven by the goal of restoring cognitive resilience for patients everywhere.
Co-Founder & CEO
Donna J. Cross, PhD
Research Professor University of Utah Department of Radiology and Imaging
Co-Founder & Director
Satoshi Minoshima, MD PhD
Professor and Anne G. Osborn endowed Chair University of Utah Department of Radiology and Imaging
Chief Science Officer
Andrew Roberts, PhD
Associate Professor University of Utah Department of Chemistry
Clinical Trials Advisor
Elaine R. Peskind, MD
Research Professor VA Puget Sound and University of Washington Department of Psychiatry and Behavioral Sciences
Advisor — Development
Claes Hornstrand, MBA
Professor and Anne G. Osborn endowed Chair University of Utah Department of Radiology and Imaging
Clinical Advisor
Nicholas A. Frost, MD, PhD
Assistant Professor University of Utah Department of Neurology
Regulatory Affairs Advisor
Carmen Betancourt Riche, MBA
40+ years experience in regulatory affairs with FDA Centers for Drugs and Biologics
Annette Lavoie, PhD
Startup business advisor for University technology spinouts
Connected expertise
Built with research, development, and commercialization partners.
The mission
Making the brain stronger against degeneration caused by disease and injury.
Our Science
Caelium’s breakthrough is built around a single therapeutic treatment designed to address a shared biological process present across many brain diseases and injuries: neurodegeneration.
While these conditions differ in cause and presentation, they are linked by progressive loss of brain structure and function. By targeting this common neurodegenerative process, Caelium’s therapy can be applied across a wide range of indications rather than developed separately for each disease.
Lead
Alzheimer’s
Pipeline
ALS & MS
Pipeline
Parkinson’s
Trauma
TBI & SCI
UPDATES
Latest News
17, May 2026
Radiology Professor Develops Novel Approaches to Treating Alzheimer’s Disease | Radiology | U of U School of Medicine
16, April 2026
Efforts by local researcher close in on Alzheimer’s treatments – Park Record
12, May 2026
Utahn may be on verge of a significant breakthrough in treating Alzheimer’s – Deseret News
Latest News
Latest News
Selected coverage, conversations, and research stories following the work forward.